Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT05605548
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
4 participants
INTERVENTIONAL
2023-02-16
2024-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
NCT00578968
Mitoquines in COPD
NCT04449419
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
NCT00239460
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
NCT02662582
Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD
NCT02161744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MitoQ
Participants will take 1 pill each day for 6 weeks
MitoQ
MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Placebo
Participants will take 1 pill each day for 6 weeks
Placebo
A look-alike inactive substance, a "sugar pill"
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MitoQ
MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Placebo
A look-alike inactive substance, a "sugar pill"
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Global Initiative for obstructive lung disease (GOLD) Stages II to IV
Exclusion Criteria
* Heart Disease
* Diabetes
* Vasoactive medications
* Uncontrolled high blood pressure
* Fluid in lungs
* Sleep apnea
* Raynaud's Phenomenon
* Gangrene of the digits
* History of coagulation
* Pregnant women
* Children
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Heart Association
OTHER
Virginia Commonwealth University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paula Rodriguez-Miguelez, PhD
Role: PRINCIPAL_INVESTIGATOR
Virginia Commonwealth University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Commonwealth University
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
905812
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
HM20021976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.